Compare AbCellera Biologics Inc (ABCL) vs Freeport-McMoRan Inc (FCX) Price & Performance

AbCellera Biologics (ABCL) has surged 12.4% to $10.97, driven by positive Phase 2 clinical trial results for its menopause treatment ABCL635. The stock shows strong technical momentum with bullish moving averages, though RSI indicates overbought conditions. Fundamentally, the company remains unprofitable with negative margins but has beaten earnings expectations in recent quarters. Analyst sentiment is overwhelmingly positive with 91.7% buy ratings and a $15.50 consensus price target.

The outlook remains speculative given ABCL's clinical-stage status and persistent losses, but recent drug development success provides significant upside potential. Key risks include clinical trial failures, cash burn concerns, and competitive pressures. The $200 million oversubscribed offering strengthens the balance sheet for continued R&D, positioning the company for potential long-term growth if pipeline assets succeed.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.